Agilent Technologies (NYSE:A) Coverage Initiated at Rothschild & Co Redburn

Stock analysts at Rothschild & Co Redburn started coverage on shares of Agilent Technologies (NYSE:A) in a research note issued to investors on Wednesday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $165.00 price target on the medical research company’s stock. Rothschild & Co Redburn’s price objective would suggest a potential upside of 17.75% from the stock’s current price.

A number of other equities research analysts have also weighed in on the stock. Evercore ISI upped their target price on shares of Agilent Technologies from $128.00 to $140.00 and gave the stock an “in-line” rating in a report on Tuesday. Barclays upped their price objective on shares of Agilent Technologies from $125.00 to $150.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 2nd. Wells Fargo & Company lifted their target price on shares of Agilent Technologies from $140.00 to $150.00 and gave the stock an “overweight” rating in a research report on Monday, September 15th. Robert W. Baird boosted their target price on Agilent Technologies from $141.00 to $142.00 and gave the stock an “outperform” rating in a research note on Thursday, August 28th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Agilent Technologies in a research note on Saturday, September 27th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $148.69.

Agilent Technologies Trading Down 0.5%

A opened at $140.13 on Wednesday. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71. Agilent Technologies has a fifty-two week low of $96.43 and a fifty-two week high of $153.84. The firm has a market capitalization of $39.73 billion, a PE ratio of 32.89, a P/E/G ratio of 4.60 and a beta of 1.26. The company’s 50-day moving average is $124.58 and its 200 day moving average is $116.94.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.37. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.67 billion. During the same quarter in the prior year, the business posted $1.32 EPS. The firm’s revenue was up 10.1% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, research analysts predict that Agilent Technologies will post 5.58 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Agilent Technologies by 13.5% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company’s stock valued at $4,279,000 after acquiring an additional 4,362 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Agilent Technologies by 8.3% during the 1st quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company’s stock valued at $3,606,000 after acquiring an additional 2,371 shares during the period. Alps Advisors Inc. grew its position in shares of Agilent Technologies by 29.5% during the 1st quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company’s stock valued at $1,563,000 after acquiring an additional 3,040 shares during the period. D.A. Davidson & CO. grew its position in shares of Agilent Technologies by 30.4% during the 1st quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company’s stock valued at $1,108,000 after acquiring an additional 2,207 shares during the period. Finally, LGT Capital Partners LTD. boosted its holdings in Agilent Technologies by 7.6% in the 1st quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company’s stock worth $89,870,000 after buying an additional 54,302 shares during the period.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.